Evaxion to Unveil Potentially Groundbreaking AI-Immunology™ Precision Cancer Vaccine Concept
- Proof of Concept – Evaxion’s AI-Immunology™ platform demonstrates success in designing precision cancer vaccines in hematological cancers by targeting a novel class of antigens
- Broad Applicability – The vaccine concept holds tremendous potential, offering broad applicability and promising benefits for patients with hematological malignancies
COPENHAGEN, Denmark, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, proudly announces the presentation of its novel precision vaccine concept at the 65th American Society of Hematology (ASH) Annual Meeting, taking place in San Diego, California, from December 9-12, 2023.
Selected for an Oral Presentation – Evaxion has been chosen for an oral presentation from a competitive pool of >5000 submitted abstracts. The presentation will unveil a breakthrough achievement using the Company’s proprietary AI target discovery and development platform, AI-Immunology™. Based upon a novel source of targets, endogenous retroviruses (ERVs), combined with unique data insights, Evaxion has discovered a novel concept for precision vaccines in hematological malignancies and selected solid cancers.
Tailored Precision Vaccines – The precision vaccines are tailored to the specific tumor profiles and immune systems of patient groups. This marks a significant stride forward in addressing the complexities of cancers, including hematological malignancies. The discovery will potentially allow for a broader than previously expected application of vaccines in cancer therapy.
Event Details:
|
Title: |
“Endogenous Retroviral Elements Constitute a Promising Vaccine Antigen Source for Hematological Malignancies” |
|
Talk: |
243 |
|
Session: |
Emerging Tools, Techniques and Artificial Intelligence in Hematology: Emerging Technologies for Understanding Benign and Malignant Hematology |
|
Session: |
803 |
|
Location: |
Room 30 – San Diego Convention Center |
|
Time: |
Saturday, December 9, 2:30 p.m. PDT |
|
Presenter: |
Anders Bundgård Sørensen, Project Director of Research and Discovery |
|
|
|
About ERVs
Endogenous retroviruses (ERVs) are remnants of ancient viruses incorporated into the human genome. While dormant in normal cells due to strict epigenetic control, cancer cells may express these traces, making ERVs ideal targets for cancer vaccines.
About EVAXION
Evaxion Biotech A/S is a pioneering TechBio company based upon its AI platform, AI-Immunology™. Evaxion’s proprietary and scalable AI prediction models harness the power of artificial intelligence to decode the human immune system and develop novel immunotherapies for cancer, bacterial diseases, and viral infections. Based upon AI-Immunology™, Evaxion has developed a clinical-stage oncology pipeline of novel personalized vaccines and a preclinical infectious disease pipeline in bacterial and viral diseases with high unmet medical needs. Evaxion is committed to transforming patients’ lives by providing innovative and targeted treatment options. For more information about Evaxion and its groundbreaking AI-Immunology™ platform and vaccine pipeline, please visit our website.
